First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI)

International Journal of Oncology

Volumn 41, Issue 4, 2012, Pages 1213-1220

  Eichler, Katrin ^a   Zangos, S ^a   Mack, M G ^a   Hammerstingl, R ^a   Gruber Rouh, T ^a   Gallus, C ^a   Vogl, T J ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Beads; Colorectal cancer; Intraarterial therapy; Liver metastases

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DEXAMETHASONE; FIRTECAN; GRANISETRON; IRINOTECAN; MEPIVACAINE; MICROSPHERE; PETHIDINE; POLYVINYL ALCOHOL;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; APPLICATION SITE PAIN; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD PRESSURE; CANCER GROWTH; CANCER RADIOTHERAPY; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DYSPNEA; FEASIBILITY STUDY; FEMALE; HEART PALPITATION; HUMAN; HYDROGEL; INOPERABLE CANCER; LABORATORY TEST; LASER THERMOTHERAPY; LEUKOCYTE COUNT; LIVER METASTASIS; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL CHEST PAIN; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; CAMPTOTHECIN; CHEMOEMBOLIZATION, THERAPEUTIC; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84866518432     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1572     Document Type: Article

References (36)

1. Fiorentini G AC, Montagnani F, Tilli M, Mambrini A, Benea G: Trans-arterial chemoembolisation of metastatic colorectal carcinoma (mCRC) to the liver adopting polyvinylalcohol microspheres loaded with irinotecan (DEBIRI) compared to FOLFIRI (CT): evaluation at two years of a phase III clinical trial. Ann Oncol 21, 2010.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
3. Pazdur R, Coia L, Hoskins WJ and Wagman LD (eds): Cancer management: a multidisciplinary approach. In: Medical, Surgical and Radiation Oncology. 7th edition. CMP Healthcare Media, New York, NY, 2004.
4. Fong Y, Cohen AM, Fortner JG, et al: Liver resection for colorectal metastases. J Clin Oncol 15: 938-946, 1997.
5. Adam R: Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 14 (Suppl 2): ii13-ii16, 2003.
6. Adam R, Delvart V, Pascal G, et al: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240: 644-658, 2004.
7. Stangl R, Altendorf-Hofmann A, Charnley RM and Scheele J: Factors influencing the natural history of colorectal liver metastases. Lancet 343: 1405-1410, 1994.
8. Scheele J, Stang R, Altendorf-Hofmann A and Paul M: Resection of colorectal liver metastases. World J Surg 19: 59-71, 1995.
9. Fong Y: Hepatic colorectal metastasis: current surgical therapy, selection criteria for hepatectomy, and role for adjuvant therapy. Adv Surg 34: 351-381, 2000.
10. Fong Y and Blumgart LH: Hepatic colorectal metastasis: current status of surgical therapy. Oncology (Williston Park) 12: 1489-1503, 1998.
11. Meyerhardt JA and Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med 352: 476-487, 2005.
12. Kennedy A, Nag S, Salem R, et al: Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 68: 13-23, 2007.
13. Germer CT, Buhr HJ and Isbert C: Nonoperative ablation for liver metastases. Possibilities and limitations as a curative treatment. Chirurg 76: 552-563, 2005 (In German).
14. Brown DB, Geschwind JF, Soulen MC, Millward SF and Sacks D: Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol 17: 217-223, 2006.
15. Bavisotto LM, Patel NH, Althaus SJ, et al.: Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: a phase II trial of the Puget Sound Oncology Consortium (PSOC 1104). Clin Cancer Res 5: 95-109, 1999.
16. Vogl TJ, Straub R, Eichler K, Sollner O and Mack MG: Colorectal carcinoma metastases in liver: laser-induced interstitial thermotherapy - local tumor control rate and survival data. Radiology 230: 450-458, 2004.
17. Fiorentini G, Aliberti C, Turrisi G, et al: Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In Vivo 21: 1085-1091, 2007.
18. Aliberti C, Tilli M, Benea G and Fiorentini G: Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res 26: 3793-3795, 2006.
19. Rofe A PS: A preclinical study to evaluate the plasma levels of irinotecan after hepatic embolisation using drug loaded in a porcine model. Institute of Medical and Veterinary Science, Adelaide, 2006.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
21. Locker GY, Hamilton S, Harris J, et al: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24: 5313-5327, 2006.
22. Chong G and Cunningham D: Improving long-term outcomes for patients with liver metastases from colorectal cancer. J Clin Oncol 23: 9063-9066, 2005.
23. Cohen AD and Kemeny NE: An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist 8: 553-566, 2003.
24. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914, 2000.
25. Leonard GD, Brenner B and Kemeny NE: Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 23: 2038-2048, 2005.
26. Llovet JM and Beaugrand M: Hepatocellular carcinoma: present status and future prospects. J Hepatol 38 (Suppl 1): S136-S149, 2003.
27. Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164-1171, 2002.
28. Llovet JM and Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37: 429-442, 2003.
29. Barber FD, Mavligit G and Kurzrock R: Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview. Cancer Treat Rev 30: 425-436, 2004.
30. Wallace S, Carrasco CH, Charnsangavej C, Richli WR, Wright K and Gianturco C: Hepatic artery infusion and chemoembolization in the management of liver metastases. Cardiovasc Intervent Radiol 13: 153-160, 1990.
31. Vogl TJ, Gruber T, Balzer JO, Eichler K, Hammerstingl R and Zangos S: Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology 250: 281-289, 2009.
32. Martin RC, Robbins K, Tomalty D, et al: Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol 7: 80, 2009.
33. Pfizer: Camptosar® - irinotecan hydrochloride injection. Prescribing information (US), 2008.
34. de Forni M, Bugat R, Chabot GG, et al: Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54: 4347-4354, 1994.
35. Pazdur R: Irinotecan: toward clinical end points in drug development. Oncology (Williston Park) 12: 13-21, 1998.
36. Lencioni R, Malagari K, Vogl T, et al: A randomized phase II trial of a drug eluting bead in the treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization. In: Proc ASCO Annual Meeting. ASCO GI, Alexandria, VA, 2009.